170 related articles for article (PubMed ID: 28888085)
1. Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma.
Jia L; Jiang Y; Michael CW
Diagn Cytopathol; 2017 Nov; 45(11):998-1004. PubMed ID: 28888085
[TBL] [Abstract][Full Text] [Related]
2. NKX3.1 as a marker of prostatic origin in metastatic tumors.
Gurel B; Ali TZ; Montgomery EA; Begum S; Hicks J; Goggins M; Eberhart CG; Clark DP; Bieberich CJ; Epstein JI; De Marzo AM
Am J Surg Pathol; 2010 Aug; 34(8):1097-105. PubMed ID: 20588175
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
[TBL] [Abstract][Full Text] [Related]
4. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
Bernacki KD; Fields KL; Roh MH
Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder.
Lane Z; Hansel DE; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1322-6. PubMed ID: 18670358
[TBL] [Abstract][Full Text] [Related]
6. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.
Huang H; Guma SR; Melamed J; Zhou M; Lee P; Deng FM
Am J Clin Exp Urol; 2018; 6(5):182-188. PubMed ID: 30510970
[TBL] [Abstract][Full Text] [Related]
7. Expression of NKX3.1, Prostatic Specific Antigen and Prostatic Specific Alkaline Phosphatase in Cytology Specimens of Metastatic Prostatic Carcinoma.
Wang M; Abi-Raad R; Adeniran AJ; Cai G
J Clin Transl Pathol; 2021 Dec; 1(1):16-20. PubMed ID: 35265947
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
9. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
Chang SS; Reuter VE; Heston WD; Gaudin PB
Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
[TBL] [Abstract][Full Text] [Related]
10. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
11. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
12. Utility of NKX3.1 Immunostaining in the Detection of Metastatic Prostatic Carcinoma on Fine-Needle Aspiration Smears.
Gan Q; Joseph CT; Guo M; Zhang M; Sun X; Gong Y
Am J Clin Pathol; 2019 Sep; 152(4):495-501. PubMed ID: 31175351
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.
Mhawech-Fauceglia P; Zhang S; Terracciano L; Sauter G; Chadhuri A; Herrmann FR; Penetrante R
Histopathology; 2007 Mar; 50(4):472-83. PubMed ID: 17448023
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males.
Abouhashem NS; Salah S
Pathol Res Pract; 2020 Oct; 216(10):153221. PubMed ID: 32979741
[TBL] [Abstract][Full Text] [Related]
15. Cellular distribution and heterogeneity of Psa and Psma expression in normal, hyperplasia and human prostate cancer.
Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Horchani A; Oueslati R
Tunis Med; 2013 Jul; 91(7):458-63. PubMed ID: 24008878
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma.
Takada N; Nishida H; Oyama Y; Kusaba T; Kadowaki H; Arakane M; Wada J; Urabe S; Daa T
Pathobiology; 2020; 87(1):30-36. PubMed ID: 31865345
[TBL] [Abstract][Full Text] [Related]
17. GAD1 is a biomarker for benign and malignant prostatic tissue.
Jaraj SJ; Augsten M; Häggarth L; Wester K; Pontén F; Ostman A; Egevad L
Scand J Urol Nephrol; 2011 Feb; 45(1):39-45. PubMed ID: 21091088
[TBL] [Abstract][Full Text] [Related]
18. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.
Mannweiler S; Amersdorfer P; Trajanoski S; Terrett JA; King D; Mehes G
Pathol Oncol Res; 2009 Jun; 15(2):167-72. PubMed ID: 18802790
[TBL] [Abstract][Full Text] [Related]
20. [Correlation study of expression levels of prostate-specific membrane antigen and prostate-specific antigen with Gleason score of prostate carcinoma].
Ren JQ; Chen ZQ; Zheng L; Chen Q; Li H; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):735-8. PubMed ID: 15733392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
